JLL to acquire all outstanding shares in Patheon

JLL Patheon Holdings has made an offer to acquire the outstanding shares of Patheon, a global provider of drug development and manufacturing services to the pharmaceutical industry.

JLL holds convertible preferred shares of the company, which when converted and taken together with its holdings of restricted voting shares, would represent approximately 29% of the restricted voting shares of the company.

Patheon will appoint a special committee of independent directors to evaluate the bid and make recommendations to the board and shareholders. The company continues to run its business as usual.

Patheon's services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms.